Observational study of patients with advanced basal cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate and characterize the profile of patients with advanced basal cell carcinoma (BCC), a common skin cancer. It will collect both retrospective and prospective data on patients diagnosed with advanced BCC, focusing on their clinical characteristics, disease progression, and treatment options. The study seeks to address the lack of accurate incidence data and improve understanding of this condition, which has seen an increase in cases and a younger average age of onset. By analyzing patient data from dermatology and oncology outpatient clinics, the study will provide valuable insights into the management of advanced BCC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male and female patients aged ≥ 18 years
2. Patients diagnosed with advanced basal cell carcinoma of the skin, i.e. tumours included in at least one of the following categories: locally advanced carcinoma (not radically treatable by surgery and/or radiotherapy), carcinoma with lymph node and/or distant metastatic localisation
3. patients who have had at least one access (first visit or follow-up visit) at the dermatology or oncology outpatient clinic of the centres involved

   * Patients diagnosed with advanced BCC who have accessed the centre from 1 January 2016 until the date of activation of the centre will be included in the retrospective cohort;
   * Patients diagnosed with advanced BCC who have accessed the centre from the date of activation
4. Signature of informed consent

Exclusion Criteria:

Patients incapable of giving informed consent

Where it's running

• Irccs Fondazione Policlinico Gemelli
  Roma, Ita, Italy Recruiting

Study contacts

• Principal investigator: Ketty MD Peris — Irccs Fondazione Policlinico Gemelli
• Study coordinator: Ketty MD Peris
• Email: ketty.peris@unicatt.it
• Phone: 0630154211

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-based risk and subtype prediction for basal cell carcinoma using dermoscopic images

  A retrospective study tests an artificial intelligence model to classify basal cell carcinoma as low- or high-risk and to predict histopathological subtypes from archived dermoscopic images.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Istanbul · NCT07677124

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• In-home cancer treatment with remote specialist support for patients in the Florida Panhandle

  This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07285044

• Vitamin D and light therapy to boost skin cancer response before surgery

  This study tests whether giving Vitamin D or a placebo around the time of a light-based treatment (PDT) can help boost skin cancer treatment before Mohs surgery or ED&C in adults with basal cell or squamous cell carcinoma.

  Recruiting Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07241585

• Using line-field confocal OCT to map Mohs surgery margins for basal cell carcinoma

  This tests whether line-field confocal optical coherence tomography (LC-OCT) can noninvasively show the edges of basal cell carcinomas in adults scheduled for Mohs surgery.

  Recruiting Roswell Park Cancer Institute · Buffalo, New York · NCT07182240

• Neoadjuvant Opdualag (nivolumab + relatlimab) versus nivolumab for resectable high-risk basal cell carcinoma

  This trial tests whether adding relatlimab to nivolumab before surgery helps people with resectable high‑risk basal cell carcinoma shrink tumors and improve surgical outcomes.

  Recruiting at 3 sites Phase 2 University of California, San Diego · Irvine, California and 2 other locations · NCT06624475

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.